Repare Therapeutics Inc. Research and Development Expense
Repare Therapeutics Inc. reported Research and Development Expense of $7.50 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-14
- Repare Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $7.50M, a 73.59% decline year-over-year.
- Repare Therapeutics Inc. research and development expense for the quarter ending 2025-06-30 was $14.28M, a 52.51% decline year-over-year.
- Repare Therapeutics Inc. research and development expense for the quarter ending 2025-03-31 was $20.27M, a 38.52% decline year-over-year.
- Repare Therapeutics Inc. research and development expense for the quarter ending 2024-12-31 was $24.50M, a 30.54% decline year-over-year.
- Repare Therapeutics Inc. research and development expense for fiscal 2024 was $115.94M, a 13.21% decline from fiscal 2023.
- Repare Therapeutics Inc. research and development expense for fiscal 2023 was $133.59M, a 12.20% increase from fiscal 2022.
- Repare Therapeutics Inc. research and development expense for fiscal 2022 was $119.07M, a 32.23% increase from fiscal 2021.
- Repare Therapeutics Inc. research and development expense for fiscal 2021 was $90.05M, a 124.61% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $7.50M 10-Q · filed 2025-11-14 | $21.79M derived: sum of 2 quarters · filed 2025-11-14 | $42.05M 10-Q · filed 2025-11-14 | $66.55M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | $14.28M 10-Q · filed 2025-08-08 | $34.55M 10-Q · filed 2025-08-08 | $59.05M derived: sum of 3 quarters · filed 2025-08-08 | $87.45M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-03-31 | $20.27M 10-Q · filed 2025-05-13 | $44.77M derived: sum of 2 quarters · filed 2025-05-13 | $73.17M derived: sum of 3 quarters · filed 2025-11-14 | $103.24M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | $24.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $52.90M derived: sum of 2 quarters · filed 2025-11-14 | $82.97M derived: sum of 3 quarters · filed 2025-11-14 | $115.94M 10-K · filed 2025-03-03 |
| 2024-09-30 | $28.40M 10-Q · filed 2025-11-14 | $58.48M derived: sum of 2 quarters · filed 2025-11-14 | $91.45M 10-Q · filed 2025-11-14 | $126.71M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $30.07M 10-Q · filed 2025-08-08 | $63.05M 10-Q · filed 2025-08-08 | $98.31M derived: sum of 3 quarters · filed 2025-08-08 | $131.02M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $32.97M 10-Q · filed 2025-05-13 | $68.24M derived: sum of 2 quarters · filed 2025-05-13 | $100.94M derived: sum of 3 quarters · filed 2025-05-13 | $134.73M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $35.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $67.97M derived: sum of 2 quarters · filed 2025-03-03 | $101.76M derived: sum of 3 quarters · filed 2025-03-03 | $133.59M 10-K · filed 2025-03-03 |
| 2023-09-30 | $32.71M 10-Q · filed 2024-11-07 | $66.50M derived: sum of 2 quarters · filed 2024-11-07 | $98.33M 10-Q · filed 2024-11-07 | $128.22M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $33.79M 10-Q · filed 2024-08-06 | $65.62M 10-Q · filed 2024-08-06 | $95.51M derived: sum of 3 quarters · filed 2024-08-06 | $126.75M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $31.83M 10-Q · filed 2024-05-07 | $61.72M derived: sum of 2 quarters · filed 2024-05-07 | $92.96M derived: sum of 3 quarters · filed 2024-05-07 | $124.44M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $29.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $61.13M derived: sum of 2 quarters · filed 2024-02-28 | $92.61M derived: sum of 3 quarters · filed 2024-02-28 | $119.07M 10-K · filed 2024-02-28 |
| 2022-09-30 | $31.24M 10-Q · filed 2023-11-09 | $62.72M derived: sum of 2 quarters · filed 2023-11-09 | $89.17M 10-Q · filed 2023-11-09 | $117.15M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $31.48M 10-Q · filed 2023-08-09 | $57.93M 10-Q · filed 2023-08-09 | $85.91M derived: sum of 3 quarters · filed 2023-08-09 | $111.27M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $26.46M 10-Q · filed 2023-05-09 | $54.43M derived: sum of 2 quarters · filed 2023-05-09 | $79.79M derived: sum of 3 quarters · filed 2023-05-09 | $100.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $27.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $53.33M derived: sum of 2 quarters · filed 2023-02-28 | $73.54M derived: sum of 3 quarters · filed 2023-02-28 | $90.05M 10-K · filed 2023-02-28 |
| 2021-09-30 | $25.36M 10-Q · filed 2022-11-09 | $45.57M derived: sum of 2 quarters · filed 2022-11-09 | $62.08M 10-Q · filed 2022-11-09 | $74.49M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $20.20M 10-Q · filed 2022-08-04 | $36.71M 10-Q · filed 2022-08-04 | $49.13M derived: sum of 3 quarters · filed 2022-08-04 | $59.22M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $16.51M 10-Q · filed 2022-05-05 | $28.93M derived: sum of 2 quarters · filed 2022-05-05 | $39.02M derived: sum of 3 quarters · filed 2022-05-05 | $47.97M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $12.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $22.51M derived: sum of 2 quarters · filed 2022-03-01 | $31.46M derived: sum of 3 quarters · filed 2022-03-01 | $40.09M 10-K · filed 2022-03-01 |
| 2020-09-30 | $10.09M 10-Q · filed 2021-11-10 | $19.04M derived: sum of 2 quarters · filed 2021-11-10 | $27.67M 10-Q · filed 2021-11-10 | $34.49M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $8.95M 10-Q · filed 2021-08-12 | $17.58M 10-Q · filed 2021-08-12 | $24.40M derived: sum of 3 quarters · filed 2022-03-01 | $30.02M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $8.63M 10-Q · filed 2021-05-13 | $15.45M derived: sum of 2 quarters · filed 2022-03-01 | $21.07M derived: sum of 3 quarters · filed 2022-03-01 | $25.92M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $12.44M derived: sum of 2 quarters · filed 2022-03-01 | $17.29M derived: sum of 3 quarters · filed 2022-03-01 | $21.00M 10-K · filed 2022-03-01 |
| 2019-09-30 | $5.62M 10-Q · filed 2020-11-12 | $10.47M derived: sum of 2 quarters · filed 2020-11-12 | $14.17M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $4.85M 10-Q · filed 2020-08-13 | $8.56M 10-Q · filed 2020-08-13 |